Geary Richard S 4/A
4/A · IONIS PHARMACEUTICALS INC · Filed Nov 7, 2025
Insider Transaction Report
Form 4/AAmended
Geary Richard S
Senior Vice President
Transactions
- Exercise/Conversion
Common Stock
2025-11-03$60.89/sh+775$47,190→ 60,432 total - Sale
Common Stock
2025-11-03$75.05/sh−775$58,167→ 59,657 total - Exercise/Conversion
Common Stock
2025-11-03$56.78/sh+905$51,386→ 60,562 total - Sale
Common Stock
2025-11-03$75.05/sh−905$67,924→ 59,657 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-03−905→ 15,538 totalExercise: $56.78From: 2023-01-02Exp: 2028-01-03→ Common Stock (905 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-03−775→ 19,101 totalExercise: $60.89From: 2024-01-04Exp: 2027-01-01→ Common Stock (775 underlying)
Footnotes (2)
- [F1]This amended Form 4 is being filed to correct the amount of shares acquired or disposed of reported in column 4
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.25 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.